Bill > HB1772

This bill establishes a comprehensive framework for New Hampshire to participate in a multistate consortium conducting clinical trials using ibogaine, a potentially groundbreaking investigational drug, for treating substance use disorder and other neurological or mental health conditions. The bill creates two new funds within the state treasury: an Ibogaine Clinical Research Trial Fund and an Ibogaine Intellectual Property Fund, and sets up a grant program administered by the Department of Health and Human Services to support these trials. Eligible grant recipients must be local entities with proven research expertise in neurological diseases, neurosurgical capabilities, and the ability to provide matching funds. The bill requires quarterly reporting on the clinical trials' progress and financial status, and mandates that any future intellectual property or commercial rights resulting from the trials will be partially used to support programs for veterans and at-risk populations. Importantly, the bill specifies that ibogaine administration would only occur after FDA approval, and would require supervision by a licensed physician to ensure patient safety. The legislation includes a minimal appropriation of $1 for fiscal year 2027 and sets an implementation timeline, with most provisions taking effect 60 days after passage and the appropriation section becoming effective on July 1, 2026. The bill represents an innovative approach to exploring potential new treatments for complex neurological and mental health conditions.

Health and Social Services

https://gc.nh.gov/bill_Status/billinfo.aspx?id=1737&inflect=2